Trump's Hiking Of FDA User Fees Unlikely To Speed Approvals
Under the White House's 2018 budget, the fees collected by the U.S. Food and Drug Administration from companies to pay for reviewing drugs and medical devices will more than double, but...To view the full article, register now.
Already a subscriber? Click here to view full article